Powder formulations of therapeutic peptides for intranasal delivery

A powder formulation of therapeutic peptides with CPPs addresses delivery challenges by enhancing mucosal permeability, providing a convenient and effective intranasal route for peptides like semaglutide.

WO2026235758A1PCT designated stage Publication Date: 2026-11-12RHINAL THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/015386
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-21
Filing Date
2026-02-16
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current methods of delivering therapeutic peptides, such as GLP-1 agonists, are limited by the need for injection, which is painful and inconvenient, and oral administration results in low bioavailability and side effects, while mucosal delivery faces barriers due to mucosal permeability and degradation.

Method used

A pharmaceutical powder formulation is developed for intranasal delivery, combining therapeutic peptides like semaglutide with cell-penetrating peptides (CPPs) such as PenetraMax, forming a precipitate that is then processed into a pharmaceutically acceptable powder using lyophilization or spray drying.

Benefits of technology

The formulation enhances mucosal permeability, allowing for effective delivery of therapeutic peptides with reduced side effects and improved bioavailability compared to injection and oral routes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026015386_12112026_PF_FP_ABST
    Figure US2026015386_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A method is provided for preparing a pharmaceutical powder formulation suitable for intranasal delivery. A therapeutic peptide is dissolved in a first solution containing a first solvent. A cell-penetrating peptide is dissolved in a second solution containing a second solvent. The first solution and the second solution are combined under conditions that allow both the therapeutic peptide and the cell-penetrating peptide to remain in solution. A precipitate is then formed from the combined solution, wherein the precipitate includes the therapeutic peptide and the cell-penetrating peptide. The precipitate then may be further processed into a pharmaceutically acceptable powder, such as by lyophilization or spray drying. In some examples, the therapeutic peptide is a GLP-1 agonist, such as semaglutide, and the cell-penetrating peptide is PenetraMax.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Atty DktNo. 010026.00004\WC>

[0002] POWDER FORMULATIONS OF THERAPEUTIC PEPTIDES FOR INTRANASAL DELIVERY

[0003] BACKGROUND

[0004]

[0001] Glucose-regulating peptides have demonstrated therapeutic potential in the treatment of such disorders as insulin-dependent diabetes mellitus (IDDM), gestational diabetes or non-insulin dependent diabetes mellitus (NIDDM), obesity and dyslipidemia. These peptides include glucagon-like peptide (GLP), e.g. GLP-1, the exendins. especially exendin-4, also known as exenatide, and amylin peptides and amylin analogs such as pramlintide. Glucose-regulating peptides most commonly are delivered by injection.

[0005]

[0002] A major disadvantage of drug administration by injection is that trained personnel often are needed to administer the drug. For self-administered drugs, many patients are reluctant or unable to give themselves injections on a regular basis. Injections can be painful, induce local site reactions and are associated with increased risk of infection. Other disadvantages of drug injection include variability of delivery results between individuals, as well as unpredictable intensity and duration of drug action.

[0006]

[0003] While oral administration may be available, certain therapeutic agents exhibit very low bioavailability. and considerable time delay in action when given by this route due to hepatic first-pass metabolism and degradation in the gastrointestinal tract. Significant gastrointestinal side effects often lead to patient non-compliance. Thus, there remains a need to develop GLP formulations that may be administered by means other than injection and oral administration.

[0007]

[0004] Mucosal administration of therapeutic compounds offers certain advantages over injection and other modes of administration, for example in terms of convenience and speed of delivery, as well as by reducing or eliminating compliance problems and side effects that attend delivery. However, mucosal delivery' of biologically active agents is limited by mucosal barrier functions and other factors. Epithelial cells make up this mucosal barrier and provide a crucial interface between the external environment and mucosal and submucosal tissues and extracellular compartments. One of the most important functions of mucosal epithelial cells is to determine and regulate mucosal permeability. In this context, epithelial cells create selective permeability barriersAtty DktNo. 010026.00004\WC>

[0008] between different physiological compartments. Selective permeability is the result of regulated transport of molecules through the cytoplasm (the transcellular pathway) and the regulated permeability of the spaces between the cells (the paracellular pathway).

[0009]

[0005] Intercellular junctions between epithelial cells are known to be involved in both the maintenance and regulation of the epithelial barrier function, and cell-cell adhesion. Tight junctions (TJ) of epithelial and endothelial cells are particularly important for cellcell junctions that regulate permeability of the paracellular pathway, and also divide the cell surface into apical and basolateral compartments. Tight junctions form continuous circumferential intercellular contacts between epithelial cells and create a regulated barrier to the paracellular movement of water, solutes, and immune cells. They also provide a second type of barrier that contributes to cell polarity’ by limiting exchange of membrane lipids between the apical and basolateral membrane domains.

[0010]

[0006] In the context of drug delivery, the ability of drugs to permeate epithelial cell layers of mucosal surfaces, unassisted by delivery -enhancing agents, appears to be related to a number of factors, including molecular size, lipid solubility, and ionization. In general, small molecules, less than about 300-1,000 Daltons, may be capable of penetrating mucosal barriers, however, as molecular size increases, permeability’ decreases rapidly. For these reasons, mucosal drug administration typically requires larger amounts of drug than administration by injection. Other therapeutic compounds, including large molecule drugs, are often refractory to mucosal deliver}’. In addition to poor intrinsic permeability, large macromolecular drugs are often subject to limited diffusion, as well as lumenal and cellular enzymatic degradation and rapid clearance at mucosal sites. Thus, in order to deliver these larger molecules in therapeutically effective amounts, cell permeation enhancing agents are required to aid their passage across these mucosal surfaces and into systemic circulation where they may quickly act on the target tissue.

[0011] SUMMARY

[0012]

[0007] According to one aspect, a method is provided for preparing a pharmaceutical powder formulation suitable for intranasal delivery. A therapeutic peptide is dissolved in a first solution containing a first solvent. A cell-penetrating peptide (CPP) is dissolved in a second solution containing a second solvent. The first solution and the second solution are combined under conditions that allow both the therapeutic peptide and the CPP toAtty DktNo. 010026.00004\WO

[0013] remain in solution. A precipitate is then formed from the combined solution, wherein the precipitate includes the therapeutic peptide and the CPP. The precipitate then may be further processed into a pharmaceutically acceptable powder using any suitable technique, such as lyophilization or spray drying.

[0014]

[0008] In some examples, the therapeutic peptide is a GLP-1 agonist, a glucagon receptor agonist, a dual agonist, a triple agonist, an amylin analog, a gut peptide hormone dual agonist, an oxyntomodulin analogue, an amylin receptor selective agonist, a beta-cell peptide hormone, an alpha-cell peptide hormone or a combination thereof.

[0015]

[0009] In some examples, the therapeutic peptide is semaglutide and the CPP is PenetraMax.

[0016]

[0010] In other examples, the therapeutic peptide is a beta-cell peptide hormone, such as insulin, and the CPP is PenetraMax.

[0017] BRIEF DESCRIPTION OF THE DRAWINGS

[0018]

[0011] A more complete understanding of the present invention and certain advantages thereof may be acquired by referring to the following detailed description in consideration with the accompanying drawings, in which:

[0019]

[0012] FIG. 1 shows solubility of semaglutide as a function of pH, with the compound exhibiting a cationic charge at low pH, an anionic charge at neutral and higher pH and an isoelectric point at pH 5.4;

[0020]

[0013] FIG. 2 shows the chromatogram for HPLC analysis of precipitated semaglutide using the solubility method; and

[0021]

[0014] FIG. 3 the chromatogram for HPLC analysis of precipitated semaglutide and PenetraMax using the purity method.

[0022] DETAILED DESCRIPTION

[0023]

[0015] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of or to the disclosure. As used herein, the singular forms '‘a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.Atty DktNo. 010026.00004\WC>

[0024]

[0016] A dash

[0025]

[0026] that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(0)NH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line or a dashed line drawn through a line in a structure indicates a specified point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.

[0027]

[0017] The term "about’’ when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximations that may vary by ( + ) or ( - ) 10%, 5%, 1%, or any subrange or a subvalue there between. In one embodiment, the term "about" when used with regard to a dose amount means that the dose may vary by + / - 10%.

[0028]

[0018] “Comprising’" or “comprises"’ is intended to mean that the compositions and methods include the recited elements, but not excluding others.

[0029]

[0019] “Consisting essentially of’ when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed disclosure.

[0030]

[0020] “Consisting of’ shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this disclosure.

[0031]

[0021] The terms “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur and that the description includes instances where said event or circumstance occurs and instances in which it does not.

[0032]

[0022] Provided are also a pharmaceutically acceptable salt, isotopically enriched analog, deuterated analog, stereoisomer, mixture of stereoisomers, and prodrugs of the compounds described herein. “Pharmaceutically acceptable” or “physiologicallyAtty DktNo. 010026.00004\WO

[0033] acceptable” refer to compounds, salts, compositions, dosage forms, and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.

[0034]

[0023] The term "‘pharmaceutically acceptable salt” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids, and salts with organic acids. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkyl amines (i.e., NH2(alkyl)), dialkyl amines (i.e., HN(alkyl)2), trialkyl amines (i.e., N(alkyl)3), substituted alkyl amines (i.e., NH2(substituted alkyl)), di(substituted alkyl) amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl) amines (i.e., N(substituted alkyl)3), alkenyl amines (i.e., NH2(alkenyl)), dialkenyl amines (i.e., HN(alkenyl)2), trialkenyl amines (i.e., N(alkenyl)3), substituted alkenyl amines (i.e., NH2(substituted alkenyl)), di(substituted alkenyl) amines (i.e., HN(substituted alkenyl)2), tri(substituted alkenyl) amines (i.e., N(substituted alkenyl)3, mono-, di- or triAtty DktNo. 010026.00004\WO

[0035] cycloalkyl amines (i.e., NH2(cycloalkyl), HN(cycloalkyl)2, N(cycloalkyl)3), mono-, di- or tri- arylamines (i.e., NH2(aryl), HN(aryl)2, N(aryl)3), or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2- dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0036]

[0024] Some of the compounds may exist as tautomers. Tautomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary' skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.

[0037]

[0025] The compounds of the disclosure, or their pharmaceutically acceptable salts include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (J?)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

[0038]

[0026] A ‘‘stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers, or mixtures thereof, andAtty DktNo. 010026.00004\WC>

[0039] includes “enantiomers,” which refers to two stereoisomers whose molecules are non- superimposable mirror images of one another.

[0040]

[0027] ‘ ‘Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

[0041]

[0028] Relative centers of the compounds as depicted herein are indicated graphically using the “thick bond” style (bold or parallel lines) and absolute stereochemistry is depicted using wedge bonds (bold or parallel lines).

[0042]

[0029] “Salts” are any positive counterion to a negative charge on a disclosed compound and any negative counterion to a positive charge on the disclosed compound.

[0043]

[0030] “Prodrugs” means any compound which releases an active parent drug according to a structure described herein in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound described herein are prepared by modifying functional groups present in the compound described herein in such a way that the modifications may be cleaved in vivo to release the parent compound. Prodrugs may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds described herein wherein a hydroxy, amino, carboxyl, or sulfhydryl group in a compound described herein is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to esters (e g., acetate, formate, and benzoate derivatives), amides, guanidines, carbamates (e.g., N, N- dimethylaminocarbonyl) of hydroxy functional groups in compounds described herein, and the like. Preparation, selection, and use of prodrugs is discussed in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A. C. S. Symposium Series; “Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, each of which are hereby incorporated by reference in their entirety.

[0044]

[0031] Compounds described herein can be prepared from readily available starting materials using known methods and procedures. It will be appreciated that where typical processAtty DktNo. 010026.00004\WO

[0045] conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0046]

[0032] As is apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and P. G. M. Wuts, PROTECTING GROUPS IN ORGANIC SYNTHESIS, Third Edition, Wiley, New York, 1999, and references cited therein.

[0047]

[0033] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as SigmaAldrich (St. Louis, Missouri, USA), ChemScene LLC (Monmouth Junction, New Jersey, USA), Ambeed Inc. (Arlington Heights, Illinois, USA), AA Blocks, Inc. (San Diego, California, USA),

[0048]

[0034] Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as FIESER A D FIESER’S REAGENTS FOR ORGANIC Synthesis, Volumes 1-15 (John Wiley, and Sons, 2016). RODD’S CHEMISTRY OF CARBON COMPOUNDS, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 2001), Organic Reactions, Volumes 1- 40 (John Wiley, and Sons, 2019), MARCH’S ADVANCED ORGANIC CHEMISTRY, (John Wiley, and Sons, 8th Edition, 2019), and LAROCK’S COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH Publishers Inc., 1989).

[0049] Therapeutic Peptides

[0050]

[0035] Therapeutic peptides are a unique class of pharmaceutical agents composed of a series of well-ordered amino acids, usually with molecular weights ranging from 500 to 5000 Da. Research into therapeutic peptides started with fundamental studies of natural human hormones, including insulin, oxytocin, vasopressin, and gonadotropin-releasingAtty DktNo. 010026.00004\WC>

[0051] hormone (GnRH), and their specific physiological activities in the human body. Glucagon-like peptide- 1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP- IRAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating.

[0052]

[0036] GLP-1 agonists were initially developed for treating type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first- line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as non-alcoholic fatty liver disease, polycystic ovary syndrome, and diseases of the reward system such as addictions.

[0053]

[0037] GLP-1 agonists work by activating the GLP-1 receptor. They slow gastric emptying, inhibit the release of glucagon, and stimulate insulin production, therefore reducing hyperglycemia in people with type 2 diabetes. They also reduce food intake and therefore body weight, making them an effective treatment for obesity.

[0054]

[0038] Dual glucose-dependent insulinotropic polypeptides (GIP / GLP-1) have been recently developed. Tirzepatide is the most advanced unimolecular dual GIP / GLP-1 receptor agonist to be used as once weekly subcutaneous injection in T2D and recently received approval by the European Medicines Agency. Because of the complementarity of action of the two incretins, tirzepatide showed better dose-dependent (5, 10 and 15mg) efficacy (greater reduction in HbAlc and body weight) than placebo, basal insulin or two GLP- 1 analogues (dulaglutide and semaglutide). Other original molecules have been built, including triple GIP / GLP-l / glucagon receptor agonists.

[0055]

[0039] Currently, FDA- approved GLP-1 agonists include exenatide (Byetta® and Bydureon®, manufactured by AstraZeneca), liraglutide (Victoza® for diabetes, Saxenda® for obesity, manufactured by Novo Nordisk), albiglutide (Tanzeum®, manufactured by GSK), dulaglutide (Trulicity®, manufactured by Eli Lilly), lixisenatide (Lyxumia® in Europe, Adlyxin® in the United States, manufactured by Sanofi), semaglutide (Ozempic® and Rybelsus® for diabetes, Wegovy® for obesity, manufactured by NovoAtty DktNo. 010026.00004\WO

[0056] Nordisk), and tirzepatide (dual GLP-1 and GIP agonist; Mounjaro® for diabetes, Zepbound® for obesity, manufactured by Eli Lilly).

[0057]

[0040] Semaglutide may be synthesized by sequential Fmoc-solid phase peptide synthesis followed by deprotection and then by coupling of the side chain fragment to the Lys 20 side chain. The preparation method involves synthesizing a pentapeptide fragment by a liquid phase method, coupling a solid-phase resin carrier and Fmoc-Gly-OH to obtain Fmoc-Gly-resin, and sequentially coupling amino acids with FmoC protections at N terminals and side chain protections according to a peptide sequence of a main chain of the semaglutide. The peptide resin then may be cracked, purified, and freeze-dried to obtain semaglutide:

[0058] Semaglutide

[0059]

[0060]

[0041] As shown in FIG. 1. the solubility of semaglutide varies significantly depending on pH.

[0061] FIG. 1 and Table 1 below show solubility over pH conditions ranging from strongly acidic (pH 1.2) to neutral / basic (pH 6.8-9.0). Semaglutide exhibits excellent solubility at lower and neutral / basic pH conditions, likely due to ionization away from the isoelectric point (at pH 5.4-5.5), leading to good aqueous compatibility.

[0062] Table 1

[0063]

[0064] Atty DktNo. 010026.00004\WC>

[0065]

[0066]

[0042] Table 2A below lists non-limiting examples of therapeutic peptides that may be used in the compositions described herein. Other peptides within the identified classes (GLP-1 agonist, amylin receptor selective agonist, etc.) also may be used.

[0067] Table 2A

[0068]

[0069] Atty DktNo. 010026.00004\WQ

[0070]

[0071] Cell-penetrating Peptides

[0072]

[0163] Cell-penetrating peptides (CPPs) are short peptides that facilitate cellular intake and uptake of molecules ranging from nanosized particles to small chemical compounds to large fragments of DNA. The “cargo’' is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions. CPPs deliver the cargo into cells, commonly through endocytosis. for use in research and medicine. Current use is limited by a lack of cell specificity in CPP-mediated cargo delivery and insufficient understanding of the modes of their uptake. CPPs typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences that contain an alternating pattern of polar, charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively. A third class of CPPs are the hydrophobic peptides, containing only apolar residues with low net charge or hydrophobic amino acid groups that are important for cellular uptake.

[0073]

[0164] CPPs are of different sizes, amino acid sequences, and charges, but CPPs generally have the ability to translocate the plasma membrane and facilitate the delivery of various molecular cargoes to the cytoplasm or an organelle. Candidates may be classified into three mechanisms: direct penetration in the membrane, endocytosis-mediated entry, and translocation through a transitory structure. CPPs are able to transport different types of cargo molecules across plasma membrane; thus, they act as molecular delivery vehicles. They have numerous applications in medicine as drug delivery agents in the treatment of different diseases including cancer and virus inhibitors, as w ell as contrast agents forAtty DktNo. 010026.00004\WC>

[0074] cell labeling. Examples of the latter include acting as a carrier for GFP, MRI contrast agents, or quantum dots.

[0075]

[0165] Table 2B below lists non-limiting examples of various CPPs that may be used in the formulations described herein.

[0076] Table 2B

[0077]

[0078]

[0205] In some examples, a composition includes semaglutide as a therapeutic peptide and PenetraMax as a CPP. Table 3 below shows the co-solubilities and ionic properties of these individual peptides across different pH conditions.

[0079] Table 3

[0080]

[0081] Atty DktNo. 010026.00004\WC>

[0082]

[0083]

[0206] Table 4 below shows the qualitative solubility of semaglutide and PenetraMax in a variety' of different solvents.

[0084] Table 4

[0085]

[0086]

[0207] The therapeutic peptide and the CPP may be combined at any suitable molar ratio. In some examples, the molar ratio ranges from about 1:900 to about 55: 1 (mM). The molarAtty DktNo. 010026.00004\WO

[0087] ratio may range, for example, from about 1:500 to about 25:1 (mM), from about 1:200 to about 10:1 (mM). or from about 1: 100 to about 5: 1 (mM).

[0088] Powder Formation

[0089]

[0208] The peptides may be purified, as needed, and precipitated / co-precipitated from the solution. The precipitate / co-precipitate then may be formed into a pharmaceutically acceptable powder formulation using any of a number of techniques, such as lyophilizing (freeze drying), spray drying or the like.

[0090]

[0209] Suitable doses may van’ over a wide range depending on a variety’ of factors including the type and / or severity of the disease or disorder, previous treatments, the general health, age, and / or weight of the individual, the frequency of treatments, the rate of release from the composition, and any other diseases present. For example, higher doses may be administered for treatments involving conditions that are at an advanced stage and / or life threatening. Dosage regimens also may be adjusted to provide the optimum therapeutic response.

[0091] Delivery Devices

[0092]

[0210] The powder formulations may be administered using any suitable delivery device, nonlimiting examples of which include gas-assisted devices as described in U. S. Patent 8,695,592 B2, U. S. Patent 7,163,013 B2 and application publication no. US 2025 / 001813 Al.

[0093] EXAMPLES

[0094]

[0211] The following examples illustrate certain aspects described herein and should not be regarded as limiting the spirit of scope of the invention, which is defined in the appended claims.

[0095] Example 1

[0096]

[0212] This example illustrates forming solutions of semaglutide and PenetraMax at a variety of different molar ratios. Specific amounts of semaglutide were dissolved in 50µL of 0.1M HC1. The resulting semaglutide-HCl solution was diluted to 1.4 mL withAtty DktNo. 010026.00004\WC>

[0097] phosphate-buffered saline (PBS, pH 6.0) containing 0.001% methylcellulose, and normalized with 0.1 M NaOH. Specific amounts of PenetraMax were dissolved in PBS (pH 6.0) containing 0.001% methylcellulose. Aliquot of semaglutide solution was added to the PenetraMax solution, mixed gently and adjusted to a specific concentration. The final pH ranged from 6-7, which is compatible with nasal administration. Table 5 below shows the results of experiments featuring molar ratios in which semaglutide < CPP.

[0098] Table 5

[0099]

[0100]

[0213] Clear solutions of semaglutide and PenetraMax were achieved when the molar ratio ranged from 1:900 to 1:10. Table 6 below shows the results of experiments featuring molar ratios in which semaglutide > CPP.

[0101] Table 6

[0102]

[0103]

[0214] It was found that clear solutions of semaglutide and PenetraMax were achieved when the molar ratio ranged from 55: 1 to 9: 1.

[0104] Example 2

[0105]

[0215] This example illustrates preparing solutions of semaglutide (5 mg / mL) stock and PenetraMax (5 mg / mL) stock in 10% w / v hydroxypropyl beta cyclodextrin (HP- -CD) in water, in a manner similar to that described in Example 1. The final pH ranged fromAtty DktNo. 010026.00004\WO

[0106] 6.5-7.5, compatible with nasal administration. The results are presented in Table 7 below.

[0107] Table 7

[0108]

[0109]

[0216] It was found that, in this example, clear solutions of semaglutide and PenetraMax were achieved when the molar ratio ranged from 22: 1 to 3: 1.

[0110] Example 3

[0111]

[0217] This example shows converting a precipitate of semaglutide and PenetraMax (CPP) to powder. Water solutions of semaglutide (100 mg in 1 mL) and PenetraMax (100 mg in 1 mL) were combined, resulting in the immediate formation of a precipitate. The precipitate was collected and placed in a centrifuge where it was processed at 7,500 rpm for 5 minutes. The supernatant and precipitate were analyzed using HPLC. The precipitate was lyophilized to form a powder. Tables 8 and 9 below shows the results for co-precipitation and subsequent conversion to powder, respectively.

[0112] Table 8

[0113]

[0114] Atty DktNo. 010026.00004\WC>

[0115] Table 9

[0116]

[0117]

[0218] Table 10 below shows the conditions used for HPLC analysis.

[0118] Table 10

[0119]

[0120]

[0219] Table 11 below provides the gradient program used for the solubility method, for which the chromatogram is shown in FIG. 2.

[0121] Table 11

[0122]

[0123]

[0220] Table 12 below provides the gradient program used for the purity method, for which the chromatogram is shown in FIG. 3.

[0124] Table 12

[0125]

[0126] Atty DktNo. 010026.00004\WO

[0127]

[0128] Example 4

[0129]

[0221] This example illustrates assessing solubility of semaglutide and PenetraMax at 1:10 and 1:100 molar ratios in water and a 70:30 v / v ethanol: water mixture at concentrations representative of a 20% w / w feed solution (excluding any additional excipients). When both components were added simultaneously to a vial with the required mass of solvent, it was found that insoluble material was present. It was determined that the order of addition is important to achieving full dissolution: when the API was dissolved first before adding the PenetraMax, a clear solution was produced. Full dissolution was achieved for all required target concentrations in the 70:30 v / v EtOFLFbO mixture when addition was performed in this order, though in water, dissolution could only be achieved for the 1:100 API: PenetraMax molar ratio, with cloudy suspensions formed for the 1:10 molar ratio samples. The solubility of the selected excipients, N-dodecyl-P-D-maltoside (■‘DDM”), tetradecyl-P-D-maltoside (“TDM”), and HP- -cyclodextrin was also assessed in the solvent systems at their highest required concentration in a 20% w / w solids feed solution. Excipients were found to be soluble at the maximum required levels with the exception of TDM in water.

[0130]

[0222] The dissolution of the formulations was assessed in pH 6 simulated nasal fluid (“SNF”).

[0131] Formulations with a 1:10 semaglutide: PenetraMax molar ratio were found to form fine opalescent suspensions, with sediment observed after 3 hours of standing. A slight opalescence was observed for 1:50 formulations, with sediment again present after 3 hours of standing. By contrast, the 1:100 formulations rapidly produced clear, colorless solutions, with no sediment visually present following 3 hours of standing.

[0132]

[0223] Eight batches of formulation, comprised of 1% w / w semaglutide with 5.5%, 27.3% or 54.6% w / w PenetraMax (1:10, 1:50 and 1: 100 molar ratios, respectively) as well as hydroxypropyl-P-cyclodextrin and 5% w / w DDM / TDM (where applicable) were spray dried using a ProCepT 4M8-TriX spray dryer equipped with an ultrasonic nozzle. The batches were produced in good yield, found to be of suitable size for nasal deliveryAtty DktNo. 010026.00004\WO

[0133] (<10% of particles <10 pm) and had expected levels of the API and PenetraMax by HPLC assay.

[0134] Example 5

[0135]

[0224] This example illustrates estimating the systemic bioavailability of intranasal semaglutide formulations using dissolution data (Example 4) and pharmacokinetic modeling.

[0136] Dissolution Profile and Fitting

[0137]

[0225] The in-vitro nasal medium dissolution data (% dissolved vs. time) was fitted using a smooth curve, such as a Weibull or Hill model. The cumulative dissolved fraction was denoted as F<diss)(t) and its time-derivative as f <diss)(t). For a Weibull fit, the equation: F(dissi(t) = 1 - exp[-(t / a)p] was used, with parameters a and (3 obtained from the data.

[0138] Nasal Clearance and Permeation

[0139]

[0226] Mucociliary clearance (MCC) removes material to the nasopharynx, with a typical adult transit time of 10-15 minutes, leading to a first-order loss rate of k(cl) = ln(2) / 15 min-1~ 0.046 min-1.

[0140]

[0227] The effective permeation rate (k(perm)) was derived from the effective permeability (P(eff)), surface area (A), and mucus volume (V(mucus)). With a conservative peptide baseline of P(eff) = 4×10-5cm / s, k(perm) ~ 0.0036 min-1.

[0141] Absorbed Fraction Calculation

[0142]

[0228] The absorbed fraction from the mucus was calculated considering dissolution, clearance, and permeation as competing first-order processes. The systemic nasal fraction is approximated by: F(nasal) ~ ∫ f(diss)(t) (k(perm) / (k(perm) + k(cl) + k(deg))) (1 - e-[(k(perm) + k(cl) + k(deg))Δt]) dt. In cases of fast dissolution (t₅₀ « 15 min), the formula simplifies to F(nasal) ≈ k(perm) / (k(perm) + k(cl) + k(deg)).

[0143] Absolute Systemic Bioavailability

[0144]

[0229] To convert to absolute bioavailability, the equation: F(absolute) ~ F(nasal) × f(post-epithelial) was used, where k(post-epithelial) accounts for additional tissueAtty DktNo. 010026.00004\WC>

[0145] binding / metabolism. For semaglutide, early reports suggest that nasal bioavailability is higher than oral but lower than subcutaneous administration.

[0146] Experimental Findings and Predictions

[0147]

[0230] A 1:100 formulation of semaglutide with PenetraMax showed rapid dissolution, achieving t₉₀ ≈ 5 min, leading to an estimated nasal bioavailability of approximately 60%. In contrast, slower dissolving formulations (1:10) yielded lower bioavailability estimates of around 10-15%. The modeling suggests that the 1:100 formulation may achieve significantly higher systemic exposure compared to the 1: 10 formulation. When running the same model without the transport molecule, predicted bioavailability was only at 5-6%.

[0148] Sensitivity Analysis

[0149]

[0231] A sensitivity overview indicates that varying the effective permeability (P<eff)) significantly impacts the estimated bioavailability, with ranges from approximately 6% to nearly 100% depending on the enhancer’s effectiveness. The analysis suggests that increasing PenetraMax enhances permeability, pushing the bioavailability closer to the clearance-limited ceiling.

[0150] Conclusions

[0151]

[0232] The findings support advancing the 1:100 semaglutide: PenetraMax formulation for further pharmacokinetic evaluation due to its favorable dissolution and predicted bioavailability’. The findings also suggest that enhancer systems are important for improving nasal bioavailability for peptide formulations.

[0152]

[0233] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of theAtty DktNo. 010026.00004\WC>

[0153] disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. Moreover, due to biological functional equivalency considerations, some changes can be made in protein structure without affecting the biological or chemical action in kind or amount. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.

[0154]

[0234] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

Claims

Atty DktNo. 010026.00004\WC>WHAT IS CLAIMED IS:

1. A method of preparing a pharmaceutical powder formulation for intranasal delivery, the method comprising:dissolving a therapeutic peptide in a first solution containing a first solvent;dissolving a cell-penetrating peptide in a second solution containing a second solvent;combining the first solution and the second solution under conditions sufficient to enable the therapeutic peptide and cell-penetrating peptide to remain in solution;forming a precipitate from the combined solution, the precipitate comprising the therapeutic peptide and the cell-penetrating peptide; and converting the precipitate into a pharmaceutically acceptable powder.

2. The method of claim 1, wherein the therapeutic peptide is selected from the group consisting of a GLP-1 agonist, a glucagon receptor agonist, a dual agonist, a triple agonist, an amylin analog, a gut peptide hormone dual agonist, an oxyntomodulin analogue, an amylin receptor selective agonist, a beta-cell peptide hormone, an alphacell peptide hormone and a combination thereof.

3. The method of claim 1 or 2, wherein the cell-penetrating peptide is selected from the group consisting of PenetraMax, TAT, penetratin, transportan, transportan 10, MPG, polyarginine (R8), SynBl, pVEC, CADY, pepFect6 / 14, tat-PEG / tat-nano and a combination thereof.

4. The method of claim 1 or 3, wherein the therapeutic peptide comprises a GLP-1 agonist.

5. The method of claim 4, wherein the GLP-1 agonist is semaglutide.

6. The method of claim 5, wherein the cell-penetrating peptide is PenetraMax.

7. The method of claim 6, wherein semaglutide and PenetraMax are combined at a molar ratio of about 1:900 to about 55:1 (mM).Atty DktNo. 010026.00004\WC>8. The method of claim 7, wherein the molar ratio ranges from about 1:500 to about 25: 1 (mM).

9. The method of claim 8, wherein the molar ratio ranges from about 1:200 to about 10: 1 (mM).

10. The method of claim 9, wherein the molar ratio ranges from about 1:100 to about 5:1 (mM).

11. The method of claim 1 or 3, wherein the therapeutic peptide comprises a beta-cell peptide hormone.

12. The method of claim 11, wherein the therapeutic peptide is insulin.

13. The method of any preceding claim, wherein the precipitate is converted to the pharmaceutically acceptable powder by lyophilization.

14. The method of any one of claims 1-12, wherein the precipitate is converted to the pharmaceutically acceptable powder by spray drying.

15. A pharmaceutical powder formulation prepared by the method of any preceding claim.